Increasingly, biomarkers play a key role in therapeutic development programs and have been shown to improve drug approval success rates by nearly three-fold.
TORONTO (PRWEB) August 13, 2020
Increasingly, biomarkers play a key role in therapeutic development programs and have been shown to improve drug approval success rates by nearly three-fold. Some biomarkers transition to become a companion diagnostic and as such, are a required test for prescribing a specific therapy. In this webinar, we’ll focus on the development journey of a biomarker from early discovery, through clinical development and ultimately to an approved, commercially available companion diagnostic test. We’ll present the example of and experience with the recently approved therascreen® FGFR mutation companion diagnostic assay which is used to assess the eligibility of patients with urothelial cancer for treatment with the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib).
Join Suso Platero, PhD, Global Leader Precision Medicine and Head Biomarker Solution Center, Covance and Jennifer Quigley, Director, Oncology Product Commercialization, LabCorp in a live webinar on Tuesday, September 1, 2020 at 11am EDT (4pm BST/UK).
For more information or to register for this event, visit Biomarker Development from Discovery Through Companion Diagnostic Commercialization.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Tel: +1 (416) 977-6555 x 352